Fundraising FoxBiotech Startups
11,050 companies tagged Biotech, with their investors and founders.
ABLi Therapeutics develops small molecule inhibitors targeting Abelson tyrosine kinases (c-Abl) to treat Parkinson's disease, Parkinson's-related neurodegenerative diseases, and other neurological conditions linked to Abl kinase dysfunction. Its RAMP drug innovation engine designs Abl kinase inhibitors, including its lead candidate risvodetinib, aimed at improved brain penetration, potency, and safety.
0 investors
Abpro develops multispecific antibody therapeutics using proprietary discovery and engineering platforms, with lead programs targeting immuno-oncology, ophthalmology, and infectious disease; its advanced TetraBi antibody candidates ABP-102 (a T-cell engager for HER2+ solid tumors in partnership with Celltrion) and ABP-201 (targeting vascular disease in the eye through a territorial partnership with Abpro Bio) are designed to provide improved efficacy and safety profiles compared to existing treatments.
0 investors
Absco Therapeutics develops a drug delivery platform based on thermogelling polymers that shift from liquid to solid at body temperature to form controlled-release depots for sustained, on-target therapy. Its lead candidate ABS005 is a non-surgical intralesional treatment for high-grade cervical intraepithelial neoplasia (CIN2/3), with the platform targeting cancers and precancers.
0 investors
0 investors
0 investors
0 investors
ACatechol develops bioinspired surface treatment technologies to prevent infections in medical devices, particularly catheters, by inhibiting biofilm formation. The company serves hospitals and medical device manufacturers seeking to reduce catheter-related bloodstream infections and sepsis.
0 investors
0 investors
0 investors
0 investors
0 investors
Accu-Break Pharmaceuticals develops patent-pending tablet technologies that let pharmaceutical tablets be swallowed whole or broken into precise half, third, or quarter doses using a pharmacologically inactive break region. Its technologies target drugmakers seeking dose flexibility, product life-cycle management, and extended patent protection.
0 investors
0 investors
Accufy develops next-generation sequencing technology for multiomic analysis to enable early disease detection. The company serves biomedical research and diagnostics markets with proprietary NGS tagging and target enrichment platforms.
0 investors
0 investors
0 investors
0 investors
0 investors
0 investors
0 investors
0 investors
Achelios Therapeutics develops therapies for chronic pain conditions including temporomandibular joint pain, migraine, and arthritis-related joint pain through repurposed and reformulated drug candidates. The company addresses unmet medical needs in chronic pain that have been underserved by larger pharmaceutical firms.
0 investors
0 investors
0 investors